Edwards Cardioband European Post-Market Study, MiBAND

NCT ID: NCT03600688

Last Updated: 2023-01-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-06-06

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To demonstrate reduction of MR with durable performance and im-provements in functional status

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

MiBAND is a prospective, single arm, European post-market study to assess the safety and efficacy of the Edwards Cardioband system. Patients will be followed up at 30D, 6months, 1, 2 and 3 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mitral Regurgitation Mitral Insufficiency Mitral Repair Mitral Valve Annuloplasty Edwards Cardioband

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Edwards Cardioband System

Transcatheter mitral valve repair

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years;
* MR (≥ 2+ by echocardiography);
* Patient is eligible to receive the Edwards Cardioband Mitral System

Exclusion Criteria

* Active bacterial endocarditis
* Severe organic lesions with retracted chordae or congenital mal-formations with lack of valvular tissue
* Heavily calcified annulus or leaflets
* Patients in whom transesophageal echocardiography is contraindicated
* Patients who cannot tolerate an anticoagulation/antiplatelet regimen
* Patients with known severe reaction to contrast agents that cannot be adequately pre-medicated.
* Pre-existing prosthetic heart valve or annuloplasty in the Mitral position
* Life expectancy of less than twelve months
* Patient is pregnant or lactating
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Edwards Lifesciences

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stephan Baldus, MD

Role: PRINCIPAL_INVESTIGATOR

Herzzentrum UniKlinik Köln

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Herz- und Diabeteszentrum NRW Bad Oeynhausen

Bad Oeynhausen, , Germany

Site Status

Berlin Charité - Campus Benjamin Franklin

Berlin, , Germany

Site Status

Universitätsklinikum Bonn

Bonn, , Germany

Site Status

Herzzentrum UniKlinik Köln

Cologne, , Germany

Site Status

Herzzentrum Universitästklinik Dresden

Dresden, , Germany

Site Status

Düsseldorf University Hospital

Düsseldorf, , Germany

Site Status

Goethe-University Frankfurt - Surgery Center

Frankfurt am Main, , Germany

Site Status

Universitätsmedizin Göttingen

Göttingen, , Germany

Site Status

Asklepios Klinik St Georg

Hamburg, , Germany

Site Status

Universtitätsmedizin Mainz

Mainz, , Germany

Site Status

Universitätsklinikum Münster

Münster, , Germany

Site Status

Policlinico Vittorio-Emanuelle

Catania, , Italy

Site Status

Ospedale del Cuore G. Pasquinucci - Fondazione Toscana Gabreile Monasterio

Massa, , Italy

Site Status

Ospedale San Raffaele

Milan, , Italy

Site Status

Azienda Ospedaliera Universitaria Pisana

Pisa, , Italy

Site Status

Policlinico San Donato

San Donato Milanese, , Italy

Site Status

University Hospital Zürich

Zurich, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany Italy Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017-10

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

CanGaroo® Registry Study
NCT04846127 COMPLETED
CTSN Embolic Protection Trial
NCT06027788 RECRUITING NA